Literature DB >> 33557213

Evolution of SARS-CoV-2 Envelope, Membrane, Nucleocapsid, and Spike Structural Proteins from the Beginning of the Pandemic to September 2020: A Global and Regional Approach by Epidemiological Week.

Paloma Troyano-Hernáez1, Roberto Reinosa1, África Holguín1.   

Abstract

Moene">nitoring n class="Species">acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genetic diversity and emerging mutations in this ongoing pandemic is crucial for understanding its evolution and assuring the performance of diagnostic tests, vaccines, and therapies against coronavirus disease (COVID-19). This study reports on the amino acid (aa) conservation degree and the global and regional temporal evolution by epidemiological week for each residue of the following four structural SARS-CoV-2 proteins: spike, envelope, membrane, and nucleocapsid. All, 105,276 worldwide SARS-CoV-2 complete and partial sequences from 117 countries available in the Global Initiative on Sharing All Influenza Data (GISAID) from 29 December 2019 to 12 September 2020 were downloaded and processed using an in-house bioinformatics tool. Despite the extremely high conservation of SARS-CoV-2 structural proteins (>99%), all presented aa changes, i.e., 142 aa changes in 65 of the 75 envelope aa, 291 aa changes in 165 of the 222 membrane aa, 890 aa changes in 359 of the 419 nucleocapsid aa, and 2671 changes in 1132 of the 1273 spike aa. Mutations evolution differed across geographic regions and epidemiological weeks (epiweeks). The most prevalent aa changes were D614G (81.5%) in the spike protein, followed by the R203K and G204R combination (37%) in the nucleocapsid protein. The presented data provide insight into the genetic variability of SARS-CoV-2 structural proteins during the pandemic and highlights local and worldwide emerging aa changes of interest for further SARS-CoV-2 structural and functional analysis.

Entities:  

Keywords:  D614G; G204R; R203K; SARS-CoV-2; envelope; genetic variability; membrane; nucleocapsid; spike; structural proteins

Mesh:

Substances:

Year:  2021        PMID: 33557213     DOI: 10.3390/v13020243

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  22 in total

1.  Evolution of SARS-CoV-2 in Spain during the First Two Years of the Pandemic: Circulating Variants, Amino Acid Conservation, and Genetic Variability in Structural, Non-Structural, and Accessory Proteins.

Authors:  Paloma Troyano-Hernáez; Roberto Reinosa; África Holguín
Journal:  Int J Mol Sci       Date:  2022-06-07       Impact factor: 6.208

2.  pH- and Calcium-Dependent Aromatic Network in the SARS-CoV-2 Envelope Protein.

Authors:  João Medeiros-Silva; Noah H Somberg; Harrison K Wang; Matthew J McKay; Venkata S Mandala; Aurelio J Dregni; Mei Hong
Journal:  J Am Chem Soc       Date:  2022-04-05       Impact factor: 16.383

3.  Extensive genetic diversity with novel mutations in spike glycoprotein of severe acute respiratory syndrome coronavirus 2, Bangladesh in late 2020.

Authors:  S Z Afrin; S K Paul; J A Begum; S A Nasreen; S Ahmed; F U Ahmad; M A Aziz; R Parvin; M S Aung; N Kobayashi
Journal:  New Microbes New Infect       Date:  2021-04-24

4.  Data-driven analysis of amino acid change dynamics timely reveals SARS-CoV-2 variant emergence.

Authors:  Anna Bernasconi; Lorenzo Mari; Renato Casagrandi; Stefano Ceri
Journal:  Sci Rep       Date:  2021-10-26       Impact factor: 4.379

5.  Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19.

Authors:  Ruei-Min Lu; Shih-Han Ko; Wan-Yu Chen; Yu-Ling Chang; Hsiu-Ting Lin; Han-Chung Wu
Journal:  Int J Mol Sci       Date:  2021-11-17       Impact factor: 5.923

6.  Persistence of infectious SARS-CoV-2 particles for up to 37 days in patients with mild COVID-19.

Authors:  Tobias Zahn; Ines Mhedhbi; Sascha Hein; Jan Raupach; Csaba Miskey; Younes Husria; Kathrin Bayanga; Detlef Bartel; Stefan Vieths; Zoltan Ivics; Doris Oberle; Brigitte Keller-Stanislawski; Marie-Luise Herrlein; Thorsten Jürgen Maier; Eberhard Hildt
Journal:  Allergy       Date:  2021-10-24       Impact factor: 14.710

7.  A framework for the promotion of ethical benefit sharing in health research.

Authors:  Anja Bedeker; Michelle Nichols; Taryn Allie; Tsaone Tamuhla; Peter van Heusden; Olorunyomi Olorunsogbon; Nicki Tiffin
Journal:  BMJ Glob Health       Date:  2022-02

Review 8.  Emerging small molecule antivirals may fit neatly into COVID-19 treatment.

Authors:  Caroline Fenton; Susan J Keam
Journal:  Drugs Ther Perspect       Date:  2022-02-28

9.  Mutational Asymmetries in the SARS-CoV-2 Genome May Lead to Increased Hydrophobicity of Virus Proteins.

Authors:  Roman Matyášek; Kateřina Řehůřková; Kristýna Berta Marošiová; Aleš Kovařík
Journal:  Genes (Basel)       Date:  2021-05-27       Impact factor: 4.096

10.  Can seasonal influenza vaccine for 2019/2020 has cross reactivity with some of SARS-CoV-2 proteins?

Authors:  Milad Zandi; Emad Behboudi; Saber Soltani
Journal:  Int J Infect Dis       Date:  2021-07-26       Impact factor: 3.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.